Skip to main content

Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy

Buy Article:

$52.00 + tax (Refund Policy)

Purpose of review

A comprehensive approach to survivorship care for women with early-stage, hormone-receptor positive breast cancer should systematically include the proactive assessment and adequate management of endocrine therapy-associated symptoms, in order to assure optimal balance between preserving quality of life (QOL) and maximizing treatment adherence. We reviewed the recent literature focused on lifestyle factors, including physical activity, diet and nutrition, weight management, smoke, and alcohol behavior, and their link with symptomatology and QOL among women receiving adjuvant endocrine therapy.

Recent findings

Recent studies confirm the safety, feasibility, and effectiveness of lifestyle interventions in mitigating several common endocrine therapy-related effects, including musculoskeletal pain, fatigue, and insomnia, and in improving physical and emotional wellbeing as well as overall health-related QOL among women with early-stage breast cancer.Summary

Healthy lifestyle behaviors have the potential to modulate the downstream impact of endocrine therapy and improve QOL among women with early-stage breast cancer. Considerations for real-world clinical care implementation emerged, including a need to evaluate the long-term uptake of healthy behaviors and facilitate the postintervention maintenance of an improved lifestyle. Some facilitators to health promotion in breast cancer survivors were also suggested, such as individualized and one-to-one supervised programs, and digital solutions providing real-time feedback, building on personalized, direct patient engagement.

Keywords: early breast cancer; endocrine therapy; lifestyle; quality of life; treatment-related toxicity

Document Type: Research Article

Affiliations: 1: Molecular predictors and new targets in oncology, INSERM Unit 981, Gustave Roussy, Villejuif 2: Molecular predictors and new targets in oncology, INSERM Unit 981, Gustave Roussy, Villejuif, Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova 3: Molecular predictors and new targets in oncology, INSERM Unit 981, Gustave Roussy, Villejuif, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Publication date: November 1, 2021

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content